Cns Pharmaceuticals Inc (CNSP)

Overview News Price History Discussions Forecast Stock Split

Cns Pharmaceuticals Inc stock is currently priced at $0.2099, with a 24-hour trading volume of 33,987. It has seen a +2.89% increased in the last 24 hours and a -39.34% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.2017 pivot point. If it approaches the $0.2122 resistance level, significant changes may occur.

Cns Pharmaceuticals Inc Stock (CNSP) Financials Data

Cns Pharmaceuticals Inc (CNSP) Net Income 2024

CNSP net income (TTM) was -$18.61 million for the quarter ending September 30, 2023, a -38.99% decrease year-over-year.

Cns Pharmaceuticals Inc (CNSP) Cash Flow 2024

CNSP recorded a free cash flow (TTM) of -$13.91 million for the quarter ending September 30, 2023, a -21.01% decrease year-over-year.

Cns Pharmaceuticals Inc (CNSP) Earnings per Share 2024

CNSP earnings per share (TTM) was -$8.26 for the quarter ending September 30, 2023, a +26.71% growth year-over-year.

Cns Pharmaceuticals Inc Stock (CNSP) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Downs Christopher	Chief Financial Officer	Feb 01 '24	Buy	0.30	66,666	20,000	103,438
Evans Carl Anthony	Director	Feb 01 '24	Buy	0.30	33,333	10,000	33,458
Gumulka Jerzy	Director	Feb 01 '24	Buy	0.30	33,333	10,000	43,006
Downs Christopher	Chief Financial Officer	Aug 22 '23	Buy	1.27	27,000	34,177	36,772
Climaco John M	Chief Executive Officer	Aug 16 '23	Buy	1.80	2,750	4,944	49,010

Cns Pharmaceuticals Inc Stock (CNSP) Latest News

Top 5 Health Care Stocks That Are Preparing To Pump In February

Benzinga

Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Benzinga

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.